tradingkey.logo
๎™

Impact Biomedical Inc

IBO
0.511USD
-0.051-9.03%
์ข…๊ฐ€ย 12/24, 13:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
6.23M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
๎™

์ž์„ธํ•œ ๋‚ด์šฉ์€ Impact Biomedical Inc ํšŒ์‚ฌ

Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.

Impact Biomedical Inc ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ IBO
ํšŒ์‚ฌ ์ด๋ฆ„Impact Biomedical Inc
์ƒ์žฅ์ผSep 16, 2024
CEOHeuszel (Frank D)
์ง์› ์ˆ˜2
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒSep 16
์ฃผ์†Œ1400 Broadfield Blvd.
๋„์‹œHOUSTON
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX โ€“ NASDAQ Basic Amex
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ77084
์ „ํ™”15852321500
์›น์‚ฌ์ดํŠธhttps://www.impactbiomedinc.com/
์ข…๋ชฉ ์ฝ”๋“œ IBO
์ƒ์žฅ์ผSep 16, 2024
CEOHeuszel (Frank D)

Impact Biomedical Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Jason Grady
Mr. Jason Grady
Director
Director
182.00
--
Mr. David K. Keene
Mr. David K. Keene
Independent Director
Independent Director
--
--
Mr. Frank D. Heuszel, CPA
Mr. Frank D. Heuszel, CPA
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Christian Zimmerman
Mr. Christian Zimmerman
Independent Director
Independent Director
--
--
Mr. Mark Suseck
Mr. Mark Suseck
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Melissa Sims
Ms. Melissa Sims
Independent Director
Independent Director
--
--
Dr. Elise Brownell
Dr. Elise Brownell
Independent Director
Independent Director
--
--
Mr. Castel B. Hibbert
Mr. Castel B. Hibbert
Independent Director
Independent Director
--
--
Mr. Todd D. Macko
Mr. Todd D. Macko
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Heng Fai (Ambrose) Chan
Mr. Heng Fai (Ambrose) Chan
Director
Director
--
--
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Jason Grady
Mr. Jason Grady
Director
Director
182.00
--
Mr. David K. Keene
Mr. David K. Keene
Independent Director
Independent Director
--
--
Mr. Frank D. Heuszel, CPA
Mr. Frank D. Heuszel, CPA
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Christian Zimmerman
Mr. Christian Zimmerman
Independent Director
Independent Director
--
--
Mr. Mark Suseck
Mr. Mark Suseck
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Melissa Sims
Ms. Melissa Sims
Independent Director
Independent Director
--
--

์ˆ˜์ต ๋ถ„์„

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
์‚ฌ์—…๋ณ„
์ง€์—ญ๋ณ„
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ๋ณด์œ  ํ†ต๊ณ„

๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Thu, Dec 4
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Thu, Dec 4
์ฃผ์ฃผ
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Chan (Heng Fai Ambrose)
0.34%
BlackRock Institutional Trust Company, N.A.
0.24%
The Vanguard Group, Inc.
0.10%
Heuszel (Frank D.)
0.09%
Two Sigma Investments, LP
0.06%
๊ธฐํƒ€
99.18%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Chan (Heng Fai Ambrose)
0.34%
BlackRock Institutional Trust Company, N.A.
0.24%
The Vanguard Group, Inc.
0.10%
Heuszel (Frank D.)
0.09%
Two Sigma Investments, LP
0.06%
๊ธฐํƒ€
99.18%
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
๋น„์œจ
Individual Investor
0.43%
Investment Advisor
0.40%
Hedge Fund
0.06%
Investment Advisor/Hedge Fund
0.05%
Corporation
0.02%
๊ธฐํƒ€
99.04%

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sun, Oct 5
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sun, Oct 5
๋ณด๊ณ  ๊ธฐ๊ฐ„
๊ธฐ๊ด€ ์ˆ˜
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
2025Q3
25
542.17K
4.45%
+223.27K
2025Q2
27
5.00M
43.10%
+213.82K
2025Q1
27
9.94M
82.23%
+3.86M
2024Q4
21
6.56M
57.06%
+6.27M
2024Q3
14
6.41M
55.73%
+6.41M

์ฃผ์ฃผ ํ™œ๋™

๎™Œ
์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
Chg %
๋‚ ์งœ
Chan (Heng Fai Ambrose)
351.56K
2.88%
-3.92M
-91.76%
Apr 04, 2025
BlackRock Institutional Trust Company, N.A.
252.73K
2.07%
+222.06K
+723.90%
Jun 30, 2025
The Vanguard Group, Inc.
32.44K
0.27%
-94.01K
-74.35%
Jun 30, 2025
Heuszel (Frank D.)
95.47K
0.78%
--
--
Sep 08, 2025
Two Sigma Investments, LP
22.70K
0.19%
+22.70K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
49.87K
0.41%
+26.67K
+114.95%
Jun 30, 2025
Document Security Systems, Inc.
21.26K
0.17%
-161.00K
-88.33%
May 27, 2025
Susquehanna International Group, LLP
30.82K
0.25%
+30.82K
--
Jun 30, 2025
UBS Financial Services, Inc.
39.73K
0.33%
+23.56K
+145.72%
Jun 30, 2025
State Street Investment Management (US)
11.80K
0.1%
--
--
Jun 30, 2025
๋” ๋ณด๊ธฐ

๊ด€๋ จ ETF

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
์ด๋ฆ„
๋น„์œจ
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
๋น„์œจ0%

์ฃผ์‹ ๋ฐฐ๋‹น๊ธˆ

๎™Œ
์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ด 0.00 USD์˜ ๋ฐฐ๋‹น๊ธˆ์ด ๋ถ„๋ฐฐ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
๋‚ ์งœ
๋ฐฐ๋‹น๊ธˆ
๊ธฐ์ค€์ผ
์ง€๊ธ‰์ผ
๋ฐฐ๋‹น๋ฝ์ผ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ถ„ํ• 

๎™Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Impact Biomedical Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Impact Biomedical Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค:
Chan (Heng Fai Ambrose)๋Š” 351.56K์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 2.88%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
BlackRock Institutional Trust Company, N.A.๋Š” 252.73K์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 2.07%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
The Vanguard Group, Inc.๋Š” 32.44K์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 0.27%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Heuszel (Frank D.)๋Š” 95.47K์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 0.78%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Two Sigma Investments, LP๋Š” 22.70K์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 0.19%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.

Impact Biomedical Inc์˜ ์ƒ์œ„ 3๋Œ€ ์ฃผ์ฃผ ์œ ํ˜•์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
Impact Biomedical Inc์˜ ์ฃผ์š” ์ฃผ์ฃผ ์œ ํ˜• ์ƒ์œ„ 3๊ฐ€์ง€๋Š”
Chan (Heng Fai Ambrose)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.์ž…๋‹ˆ๋‹ค.

Impact Biomedical Inc(IBO)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2025Q3 ๊ธฐ์ค€์œผ๋กœ, Impact Biomedical Inc์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 25๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 542.17K๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 4.45%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q2 ๋Œ€๋น„ -38.65% ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.

Impact Biomedical Inc์˜ ์ตœ๋Œ€ ์ˆ˜์ต์›์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
-- ๊ธฐ์ค€, Impact Biomedical Inc์˜ -- ๋ถ€๋ฌธ์ด ๊ฐ€์žฅ ๋†’์€ ๋งค์ถœ์„ ๊ธฐ๋กํ–ˆ์œผ๋ฉฐ, ๊ธˆ์•ก์€ --๋กœ ์ „์ฒด ๋งค์ถœ์˜ --%๋ฅผ ์ฐจ์ง€ํ–ˆ์Šต๋‹ˆ๋‹ค.
KeyAI
๎™